Evidence map›Paper›PMID 41062840›Full record

ReviewDiscover nano2025

Phytochemical based on nanoparticles for neurodegenerative alzheimer disease management: Update review.

Basma Youssef, Ehab A Ibrahim, Said S Moselhy, Shaimaa ElShebiney, Walaa K Elabd

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Basma YoussefBiochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.
Ehab A IbrahimBiochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.
Said S MoselhyBiochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt. moselhy6@hotmail.com.
Shaimaa ElShebineyDepartment of Narcotics, Ergogenics and Poisons National Research Centre, Cairo, Egypt.
Walaa K ElabdBiochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is one of the most common chronic neurodegenerative diseases and dementia, with about 46 million cases worldwide and going to become tripled by 2050. It is characterized by formation and aggregation of amyloid-β plaques, tau tangles, and inflammatory mediators. The treatment protocol poses challenging obstacles particularly, effectiveness drug delivery to the brain. However, the available therapies with low potency and blood-brain barrier (BBB) are most challenges for developing novel treatments. New delivery systems that interact with biological systems at the molecular level, such as nanotechnology can overcome these problems and open new therapeutic avenues. Nanoparticles showed different applications in medicine due to its bioavailability, transport and low toxicity. This review explored the therapeutic potential of natural phytochemical nanomedicine that important in AD treatment through improving drug delivery system across BBB, increasing bioavailability and minimizing neurotoxicity.

Indexed as

Alzheimer's diseaseBlood-brain barrierDementiaNano-medicine

Identifiers

PMID41062840
PMCPMC12508342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.